3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
186
HER2-positive Breast Cancer
18
Neoplasm Metastasis
6
Inflammatory Breast Neoplasms
5
Triple Negative Breast Neoplasms
4
Neoplasms
4
Prostatic Neoplasms
3
Pathologic Complete Response
3
Pancreatic Neoplasms
3
HER2-positive Early Breast Cancer
3
Endometrial Neoplasms
3
Breast Neoplasms, Male
3
Anatomic Stage I Breast Cancer AJCC v8
3
Stomach Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Locally Advanced Breast Cancer
2
Hematologic Neoplasms
2
HER2-positive Metastatic Breast Cancer
2
Gastrointestinal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Ductal, Breast
2
Breast Diseases
2
Brain Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thrombocytosis
1
Interventions
Carvedilol
3
sacubitril and valsartan sodium hydrate drug combination
2
dapagliflozin
2
pertuzumab
1
nicotinamide-beta-riboside
1
empagliflozin
1
candesartan
1
Trastuzumab
1
Specimen Handling
1
Secondary Prevention
1
Perindopril
1
Ogivri
1
Metoprolol
1
Exercise
1
Electronic Health Records
1
Echocardiography
1
Carnitine
1
Bisoprolol
1
Adrenergic beta-Antagonists
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Heart Failure
×
pertuzumab
×
Breast
×
Clear all
NCT04680442
2025-04-06
SCHOLAR-2
Population Health Research Institute
Phase 2
Recruiting
130 enrolled